Videos

“I had long thought that vitamin D deficiency could be a risk factor for prostate cancer,” says Adam B. Murphy, MD, MBA, MSCI.

Tanya Dorff, MD, discusses findings from a phase 1 clinical trial that explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer.

Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.

Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.

"Anatomic radical prostatectomy really transformed radical prostatectomy from a very morbid operation with high risk, performed rarely, to one that became a commonly utilized treatment for prostate cancer," says Christopher L. Amling, MD, FACS.

Zeyad Schwen, MD, highlights 5 studies in prostate cancer being presented at the 2022 American Urological Association Annual Meeting.

Nima Almassi, MD, highlights 5 studies in bladder cancer being presented at the 2022 American Urological Association Annual Meeting.

Amy Krambeck, MD, highlights 6 studies in BPH and urinary stones being presented at the 2022 American Urological Association Annual Meeting.

“For the first time, we have 20-year follow-up data after the penile prosthesis,” says Mohit Khera, MD, MBA, MPH.

Amy M. Pearlman, MD, highlights 6 studies in sexual dysfunction and infertility being presented at the 2022 American Urological Association Annual Meeting.

A panel of experts review whether bone scans still have a place in prostate cancer imaging.

Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.

"Micro TESE is associated with higher sperm retrieval rates compared with conventional testicular sperm extraction, so this approach has really become the gold standard for sperm extraction in patients with non-obstructive azoospermia," says Denise Asafu-Adjei, MD, MPH.

“Mitomycin gel, or Jelmyto, is the first agent that gives us a chance to be able to treat these low-grade upper tract cancers of the ureter and the kidney and prevent their recurrence,” says Munver.

"This non face-to-face care coordination done 'incident to' to the provider...is reimbursable through chronic care management codes," says Shirley Lee, CRNP-FNP, MPH.

“leva can help women successfully do pelvic floor muscle training and experience symptom resolution,” says Samantha Pulliam, MD.

“We really need to listen to what people care about and speak to that,” says Shirley Lee, CRNP-FNP, MPH.

Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.

A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.

“Any kind of complicated cancer surgery requires an experienced team from beginning to end,” says David Lee, MD.

“We had fantastic completion of the study, and we were very pleased with the results,” says Samantha Pulliam, MD.

"β3 agonists really provided a new drug class of medications for patients with overactive bladder. Previously, there were no alternatives," says Ekene Enemchukwu, MD, MPH.

“We talked about patient buy in but family caregiver buy in is just as important, especially when we're talking about cancer,” says Shirley Lee, CRNP-FNP.

“This is a unique device in that it shows motion-based biofeedback,” says Samantha Pulliam, MD.

Judd W. Moul, MD, FACS, wraps up by discussing remaining unmet needs and potential future improvements in imaging modalities for prostate cancer screening.

An expert urologic oncologist revisits a patient profile and discusses how he would have approached the patient’s prostate cancer screening process.

Judd W. Moul, MD, FACS, gives a real-world overview of how the exosome-based test is used in clinical practice.

An overview of the clinical validity and utility of a urine-based, exosomal molecular test for prostate cancer screening and risk assessment.

Judd W. Moul, MD, FACS, provides insight into the timing of biomarker testing in the prostate cancer screening process, and discusses which patients might benefit the most from testing.

Judd W. Moul, MD, FACS, introduces available blood- and urine-based biomarker tests for prostate cancer screening, and discusses how they might overcome limitations of commonly used modalities.